Piramal Pharma Limited announced its unaudited standalone and consolidated financial results for Q2 2025. The company reported a consolidated loss before tax of ₹179.30 million, a stark contrast to the ₹35.38 million profit in the previous year. Total income stood at ₹4,101.44 million. The board of directors approved these results at a meeting held on November 5, 2025.
Financial Performance Overview
Piramal Pharma Limited (PPL) has released its unaudited financial results for the second quarter of the Indian Financial Year 2025 (Q2 2025), ending September 30, 2025. Key highlights from the consolidated results reveal a mixed financial landscape.
Key Financial Figures
The company’s consolidated total income for Q2 2025 amounted to ₹4,101.44 million. However, PPL reported a loss before tax of ₹179.30 million. Profit After Tax stood at ₹(180.92) million for the period ended September 30, 2025. The earnings per share was at ₹(1.37).
Segment Performance
Piramal Pharma operates primarily within a single segment, and therefore, a detailed segment-wise breakdown was not disclosed in the announcement.
Exceptional Items
During Q2 2025, PPL recognized a gain of ₹20.74 crores as exceptional items due to reimbursement of claims. This related to the insolvency of a supplier to its subsidiary, Piramal Critical Care Inc.
Standalone Financials
The standalone total income for Q2 2025 was ₹2,480.03 million, with a profit before tax of ₹389.99 million and a profit after tax of ₹309.47 million.
Critical Care Supplier Resolution
A key event during the quarter was the completion of proceedings under the Insolvency and Bankruptcy Code (IBC) related to a supplier for Piramal Critical Care Inc. A resolution plan was approved, and PPL was reimbursed for its claim on a pro-rata basis.
Source: BSE
